Boehringer Ingelheim Corporation Release: More Time, More Lives: New Authorisation to Make Life-saving Treatment Available to Ischaemic Stroke Patients Presenting Within 4.5 Hrs After the Onset of Stroke Symptoms

BRACKNELL, England--(BUSINESS WIRE)-- More ischaemic stroke patients in the UK will be eligible for the potentially life-saving treatment ‘thrombolytic’, thanks to the new authorisation of an extended treatment window for the clot-busting drug Actilyse® (alteplase, rt-PA).